MMP-2 inhibits PCSK9-induced degradation of the LDL receptor in Hepa1-c1c7 cells

5Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Low-density lipoprotein receptor (LDLR) catalyzes the uptake of LDL-cholesterol by liver and peripheral organs. The function of the LDLR is antagonized by pro-protein convertase subtilisin/kexin type 9 (PCSK9), which binds to LDLR at the plasma membrane inducing LDLR degradation. Here, we report that matrix metalloproteinase-2 (MMP-2) interacts with and cleaves PCSK9, as evidenced by proteomic, chemical cross-linkage, blue native-PAGE and domain-specific antibodies Western blot analyses. Furthermore, MMP-2 overexpression renders Hepa1-c1c7 cells resistant to PCSK9-induced LDLR degradation. The data suggest that pathological MMP-2 overexpression may protect the LDLR from PCSK-9-induced degradation.

Cite

CITATION STYLE

APA

Wang, X., Berry, E., Hernandez-Anzaldo, S., Sun, D., Adijiang, A., Li, L., … Fernandez-Patron, C. (2015). MMP-2 inhibits PCSK9-induced degradation of the LDL receptor in Hepa1-c1c7 cells. FEBS Letters, 589(4), 490–496. https://doi.org/10.1016/j.febslet.2015.01.007

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free